Expert Interview
A look at Alnylam's vutrisiran and the positive topline results from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), and discussion of emerging data for Nex-Z and nucresiran
Ticker(s): ALNYInstitution: Baylor University
- Professor of Medicine and Associate Chief of Cardiology
- Studies the molecular mechanisms of cardiovascular development in understanding of heart development for the creation of novel regenerative approaches to treat heart diseases.
- Research Interests include; Cardiac Regeneration, Advanced Heart Failure, and Mechanical Circulatory Support.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
